NewsBenzingaPepGen anuncia datos de su estudio de Fase 2 FREEDOM2-DM1 de PGN-EDODM1, que demuestran una corrección media del empalme del 46,5%; PGN-EDODM1 mostró una alta tolerabilidad; PepGen anuncia datos de su estudio de Fase 2 FREEDOM2-DM1 de PGN-EDODM1, que demuestran una corrección media del empalme del 46,5%; PGN-EDODM1 mostró una alta tolerabilidad; Benzinga 2026.11.10 12:07 (GMT+0) Open on Benzinga Other news Ardent Health Stock Tumbles 14.61% After Hours: Here's Why Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Elon Musk Had a Facepalm Moment After Sean Duffy Defends Rejecting Free Starlink for FAA: ‘Our Airspace Is Very Big’ Iridex (NASDAQ: IRIX) Shares Fall 26.96% After Hours: What Investors Should Know ‘The Noise Will Work Itself Out in Time’: AMD CEO Lisa Su Says Nvidia a ‘Phenomenal Company’ After Jensen Huang Exits Morning Bid: Jensen Huang's last hurrah, and a nervy future for Nvidia
Lowe's Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Elon Musk Had a Facepalm Moment After Sean Duffy Defends Rejecting Free Starlink for FAA: ‘Our Airspace Is Very Big’
‘The Noise Will Work Itself Out in Time’: AMD CEO Lisa Su Says Nvidia a ‘Phenomenal Company’ After Jensen Huang Exits